Emergent Science: Multi-Cancer Early Detection Tests

Share

"We support evidence-based development of innovative strategies for early detection that have the potential to improve lives. When there is FDA approval and clear demonstration of clinical benefit, we believe that equitable access to these new technologies is imperative."
- Dr. Karen Knudsen, CEO, ACS CAN

Early screening for cancer is important because when detected at later stages, treatments are more limited, and outcomes are generally poorer. While more research is needed to assess the impact on outcomes, newer, innovative multi-cancer screening technology may have the potential to detect more cancers at earlier stages. Several private and academic entities are currently developing multi-cancer early detection blood-based tests. Published data indicate that some of these tests can screen for many cancers at the same time, including some rare cancers.

They call it a Multi-Cancer Early Detection (MCED) test. We call it a potentially innovative, game-changing advancement for cancer patients.

Now we need to ensure that, if approved by the FDA and shown to have clinical benefit, millions of people, especially older Americans at higher risk for cancer, will have the test covered by their health insurance plan. We are asking Congress to pass legislation that lays the groundwork for this to happen.

Take Action

Woman with headscarf with her mother

Ending cancer as we know it starts today.

Send a message to your members of congress asking them to pass a year-end package that prioritizes policies to prevent, detect, and effectively treat cancer.

Latest Updates

March 1, 2022
Colorado

A virtual event held by ACS CAN and U.S. Sen. Michael Bennet highlighted the promise of new blood-based cancer screening technologies that have the potential to dramatically increase early-stage diagnosis for a wide range of cancers and called on Congress to pass the Multi-Cancer Early Detection Screening Coverage (MCED) Act.

February 2, 2022

The President announced this morning he is ‘reigniting’ his commitment to ‘end cancer as we know it,’ building on the initial and robust cancer moonshot investment in discovery, prioritizing increased uptake of prevention and addressing health disparities.

January 18, 2022
New York

Governor Hochul has released her Executive Budget for the next fiscal year. ACS CAN is asking for increases in funding for the Cancer Services Program and tobacco control.

September 22, 2021
National

ACS CAN is advocating for a pathway for Medicare coverage for innovative cancer early detection, once Multi-Cancer Early Detection Tests are FDA approved and clinical benefit is shown.

Emergent Science: Multi-Cancer Early Detection Tests Resources

On March 16, 2021, Representatives Terri Sewell (D-AL) and Jodey Arrington (R-TX) re-introduced the Multi- Cancer Early Detection Screening Coverage Act, H.R. 1946. On May 27, 2021, Senators Mike Crapo (R-ID) and Michael Bennet (D-CO) introduced the Senate companion, S. 1873. This legislation will create a pathway to allow Medicare to cover multi-cancer screening tests once the tests have been approved by the FDA. ACS CAN has endorsed this legislation.

Early screening for cancer is important because when detected at later stages, treatments are more limited, and outcomes are generally poorer. Newer, innovative multi-cancer screening technology has the potential to detect more cancers at earlier stages. Several private and academic entities are currently developing multi-cancer early detection blood-based tests. Published data indicate that some of these tests can screen for many cancers at the same time, including some rare cancers.